Somapacitan-beco Side Effects
Medically reviewed by Drugs.com. Last updated on May 14, 2023.
Applies to somapacitan-beco: subcutaneous solution.
Metabolic
Elevated phosphate and creatine phosphokinase occurred intermittently and were non-progressive.[Ref]
Very common (10% or more): Elevated phosphate (17.5%)
Common (1% to 10%): Elevated creatine phosphokinase, blood creatinine kinase increase, weight increased
Frequency not reported: Glucose intolerance, diabetes mellitus, fluid retention[Ref]
Nervous system
Common (1% to 10%): Sleep disorder, dizziness
Frequency not reported: Intracranial hypertension[Ref]
Endocrine
Common (1% to 10%): Adrenal insufficiency, hypoadrenalism, hypothyroidism[Ref]
Gastrointestinal
Common (1% to 10%): Dyspepsia, vomiting
Frequency not reported: Pancreatitis[Ref]
Hypersensitivity
Frequency not reported: Severe hypersensitivity[Ref]
Musculoskeletal
Very common (10% or more): Back pain (10%)
Common (1% to 10%): Arthralgia[Ref]
Hematologic
Common (1% to 10%): Anemia[Ref]
Oncologic
Frequency not reported: Neoplasms[Ref]
Other
Common (1% to 10%): Peripheral edema
Frequency not reported: Increased mortality in patients with acute critical illness[Ref]
Cardiovascular
Common (1% to 10%): Hypertension[Ref]
Local
Frequency not reported: Lipohypertrophy, lipoatrophy[Ref]
Respiratory
Common (1% to 10%): Tonsillitis[Ref]
More about somapacitan-beco
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: growth hormones
- Breastfeeding
Patient resources
Other brands
Related treatment guides
References
1. "Product Information. Sogroya (somapacitan)." Novo Nordisk Pharmaceuticals Inc (2020):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.